CKD-386
- Generic Name
- CKD-386
A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(2)
Phase 1
Completed
- Conditions
- Hypertension and Dyslipidemia
- Interventions
- Drug: D013, D326, D337
- First Posted Date
- 2021-01-05
- Last Posted Date
- 2021-07-07
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 62
- Registration Number
- NCT04694989
- Locations
- 🇰🇷
H Plus Yangji Hospital, Seoul, Gwanak-gu, Korea, Republic of
A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386
Phase 1
Completed
- Conditions
- Hypertension and Dyslipidemia
- Interventions
- Drug: D012, D326, D337
- First Posted Date
- 2020-12-17
- Last Posted Date
- 2021-07-07
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 66
- Registration Number
- NCT04673864
- Locations
- 🇰🇷
H Plus Yangji Hospital, Seoul, Gwanak-gu, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath